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ABSTRACT
Objectives. Cancer and type 2 diabetes (T2D) are two
commondiseasesthatmayshareriskfactors.Weaimed
at determining subsequent cancer risks in patients hos-
pitalized for T2D in Sweden.
Methods. T2D patients were obtained from the na-
tionwide Hospital Discharge Register; cancers were
recorded from the Swedish Cancer Registry. Standard-
ized incidence ratios (SIRs) were calculated for cancer
following last hospitalization for T2D. The comparison
group was the general Swedish population.
Results. The number of hospitalized T2D patients
from 1964 to 2007 was 125,126, of whom 26,641 had an
affected family member. Altogether 24 cancers showed
an elevated risk when follow-up was started after the
last hospitalization. The highest SIRs were for pancre-
atic (6.08) and liver (4.25) cancers. The incidences of
these cancers were even elevated when follow-up was
started 5 years after the last hospitalization for T2D,
with primary liver cancer showing the highest SIR of
4.66. Also increased were the incidences of upper aero-
digestive tract, esophageal, colon, rectal, pancreatic,
lung, cervical, endometrial, ovarian, and kidney can-
cers. Prostate cancer showed a lower risk. Familial T2D
patients showed no exceptional elevated cancer risks but
their prostate cancer and melanoma risks were lower.
Conclusions. This study, covering approximately one
half of Swedish T2D patients, showed an elevated risk
for several cancers after hospitalization for T2D, prob-
ably indicating the profound metabolic disturbances of
theunderlyingdisease.Thehighestriskswerefoundfor
liver and pancreatic cancers. No excess cancer risks
were observed in familial diabetics. The lower risk for
prostate cancer remains intriguing. The Oncologist 2010;
15:548–555
INTRODUCTION
Type 2 diabetes (T2D) is considered to be one of the major
public health challenges. The prevalence of T2D is in the
range of 2%–10% in industrialized countries, with an in-
creasing trend [1–3]. T2D is characterized by a loss of met-
abolicfuelhomeostasiscausedbyinsulinresistance,thatis,
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The Oncologist 2010;15:548–555 www.TheOncologist.comthe inability of tissues to respond to insulin [4]. As the nor-
mal functions of insulin, including the control of glucose
uptakeintoperipheraltissuesandsuppressionoftherelease
of stored lipids from adipose tissue, become defective, hy-
perglycemiaanddyslipidemiafollow.Thechronicincrease
in circulating glucose and lipid levels can further impair in-
sulinsecretionandleadtoprogressive-cellfailure.T2Dis
often associated with and preceded by obesity and meta-
bolic syndrome [5]. The disease is thought to be caused by
environmental and inherited factors in about equal propor-
tions [6]. Many environmental risks factors are known, and
they include obesity, sedentary lifestyle, low or high birth
weight, stress, nutritional factors, and toxins [1, 2]. To-
bacco smoking has been found to be a risk factor with a rel-
ative risk of about 1.6 for smokers of one pack or more per
day[7].Thedataonalcoholconsumptionarecontroversial,
butmostdatasuggestaU-shapedrelationshipbetweencon-
sumption and T2D [8]. Family history is an important risk
factor that has been shown in twins and singleton siblings
[1, 6, 9–13]. Recent genetic studies have revealed some 20
genes/loci to be associated with T2D [6, 12]. T2D is also
manifested in rare Mendelian forms that account for
2%–5% of all cases and that are of early onset [6]. Some
10% of T2D patients could be diagnosed with latent auto-
immune diabetes of the adult [14, 15].
T2D shares risk factors with cancer, such as obesity and
sedentary lifestyle. It is also conceivable that the chronic
metabolic and hormonal disturbances that are characteris-
tics of T2D predispose to cancer; these include aberrations
in the insulin-like growth factor pathway and steroid hor-
monemetabolism[16–18].Consequently,thereisevidence
that T2D is associated with elevated risks for and mortality
fromliver,pancreatic,breast,endometrial,kidney,bladder,
and colorectal cancers and non-Hodgkin’s lymphoma
[16–22].
In the present study, we assessed subsequent cancer
risks in T2D patients first hospitalized for T2D at age 39
years. The age limit and some other inclusion criteria were
applied because “diabetes mellitus” has been distinguished
as T2D only since 1997. The present nationwide study on
125,126 T2D patients is the largest yet published and has
statistical power to address cancer risk at sites for which
data are lacking or inconclusive. As a novel approach, a
separate analysis of patients with a family history of T2D
was carried out in order to test for shared genetic and envi-
ronmental risk factors for T2D and cancer.
MATERIALS AND METHODS
All the databases used in this study were nationwide, cov-
eringthewholepopulationofSwedenoveradefinedperiod
of time (9.0 million in 2005). The research database used
for this study was a subset of the national MigMed 2 data-
sets at the Center for Primary Health Care Research,
Malmö, Lund University. The MigMed database was com-
piled using data from several national Swedish registers
provided by Statistics Sweden, including the Multigenera-
tion Register, in which persons (second generation) born in
Sweden in 1932 and thereafter are registered shortly after
birth and are linked to their parents (first generation). Sib-
ships could be defined for the second generation. National
CensusData(1960–1990)andtheSwedishpopulationreg-
ister (1990–2001) were incorporated into the database to
obtain information on individuals’ socioeconomic status.
Dates of hospitalization for T2D were obtained from the
Swedish Hospital Discharge Register for the years 1964–
2007. Patients registered for hospitalization stayed at least
one night in the hospital, usually in wards with specialists;
the Register does not include outpatients in hospitals or
health care centers. Diagnoses were reported according to
the different versions of the International Classification of
Diseases (ICD), and only the primary diagnosis was con-
sidered. The codes for T2D and type 1 diabetes were first
separatedinICD-10(1997)andwethusincludedonlypa-
tients aged 39 years at first hospitalization; this age limit
isthesameoneusedbytheNationalSwedishDiabetesReg-
istry [23]. Further, in order to minimize the number of pa-
tients with type 1 diabetes, from 1997 onward, only the
diagnosis of T2D was accepted and anyone who was diag-
nosedwithanynon-T2DdiagnosisinICD-10wasremoved
from the analysis. All linkages were performed using the
national 10-digit civic identification number that is as-
signedtoeachpersoninSwedenforhisorherlifetime.This
number was replaced by a serial number for each person in
order to provide anonymity and to check that each individ-
ualwasenteredonlyonce,forhisorherfirsthospitalization
for T2D. Mistakes in the civic identification number are
rare because it contains a control code. For cancer registra-
tion, the accuracy is very high because of established rou-
tines [24]. Quality checks on the Hospital Discharge
Register have shown large differences based on, for exam-
ple, diagnosis, hospital, and time, with coding errors given
at 6%–8%; no representative data are available for T2D.
However, the very high familial risks that we have reported
for T2D in families of multiple affected individuals would
not be possible without a reasonable diagnostic accuracy
[13] (see also Discussion). Over 11.8 million individuals in
3.5 million families were included in this database; 8.9
million individuals belonged to the second generation,
which had reached the age of 75 years at the end of the fol-
low-up, which spanned 1964–2007 [25]. Family history
was defined through hospitalization for T2D in a first-
degree relative [13].
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ish Cancer Registry. Person-years of follow-up were calcu-
lated from the start of follow-up on January 1, 1964 until
hospitalization for T2D, death, emigration, or the closing
date, December 31, 2007. The median follow-up time was
15 years from the last hospitalization, 13 years when the
follow-up was started 1 year later, and 9 years when it was
started 5 years later. Last hospitalization and the various
follow-uptimeswereusedinordertoreducethepossibility
for biased surveillance in patients who underwent treat-
ment. Standardized incidence ratios (SIRs) were calculated
as the ratio of observed to the expected number of cases.
Expected numbers were calculated for anyone not hospital-
izedforT2D,thatis,forthewholeSwedishpopulation39
years old and not hospitalized for T2D. The expected num-
bers were calculated as age (5-year groups), sex, period (5-
year groups), region, and socioeconomic status–specific
standard incidence rates. An additional adjustment was
made for hospitalization for obesity using codes ICD-7 
287.00,287.09;ICD-8277.99;ICD-9278A;andICD-
10  E65-E68 [26]. In total, 30,020 individuals were hos-
pitalized for obesity and 1,171 of those were T2D patients.
Ninety-five percent confidence intervals (95% CI) were
calculated assuming a Poisson distribution, and they were
adjusted for dependence between sibling pairs [27].
The study was approved by the regional ethical review
board at Lund University.
RESULTS
The number of T2D patients aged 39 years at first hospi-
talization and fulfilling the other entrance criteria was
125,126, of whom 51,468 were first hospitalized at age
69years;26,641patientshadanaffectedfamilymember.
In Table 1, the first columns show the number of cases and
incidences in the reference population, those not hospital-
ized for T2D. The SIR for the reference population was
1.00. Follow-up for cancer was started after last hospital-
izationforT2D.CancerrisksforT2Dpatientsareshownin
Table 1 separately for the whole follow-up period (All) and
forthefollow-upthatstarted1year(All1)or5years(All
5) after hospitalization for T2D, because the SIRs were
higherforAllthanfortheotherfollow-upperiods,probably
because of a concomitant diagnosis of T2D and cancer.
This was seen in the decreasing SIRs for all cancers, 1.78
for All, 1.37 for All 1, and 1.15 for All 5. Only sites
with 50 cases or significant SIRs for the All period are
shown. For the All period, the highest SIRs were for pan-
creatic (6.08) and liver (4.25) cancers, and liver cancer
showed the highest SIR of 3.12, even in the All 5 period.
Notably, the risk for primary liver cancer was higher than
thoseforgallbladderandextrahepaticbileducttumors;the
SIRwas4.66intheAll5period.Inthatfollow-upperiod,
even the risks for upper aerodigestive tract, esophageal, co-
lon, rectal, pancreatic, lung, cervical, endometrial, ovarian,
and kidney cancers were significant.
Familial T2D patients (only data for the All 1 period
are shown in Table 1) had no difference in risk for all can-
cers (1.04) than all patients (1.37), which was influenced in
part by the significantly lower risk for prostate cancer
(0.54) in the familial patients than in all patients (0.84). In
familialT2Dpatients,theriskforprostatecancerdecreased
in a uniform fashion according to the number of hospital-
izations, reaching a SIR of 0.43 (n  13; 95% CI, 0.23–
0.74) for three to five hospitalizations and 0.10 for more
than five hospitalizations (n  1; 95% CI, 0.00–0.58). The
risk for pancreatic cancer was significantly lower in famil-
ial than in all patients (2.41 and 3.57, respectively). Some
cancers that had higher risks in all patients were not higher
in familial patients because of the lower number of cases.
However, the risk for melanoma was lower only in familial
patients (0.67).
The SIRs for all sites combined were about 0.2 decimal
unitshigherforwomenthanformen,whichwasmainlyex-
plainedbythelowSIRforprostatecancer(datanotshown).
Compared with the All 5 period in Table 1, only the male
SIR of 4.09 for liver cancer was significantly greater (n 
161; 95% CI, 3.48–4.77). For females for the All 5 pe-
riod, the SIRs were higher for gastric cancer (1.51; n  51;
95% CI, 1.12–1.98) and for nervous system tumors (1.43;
n38;95%CI,1.01–1.96).Formelanoma,thefemaleSIR
was lower at 0.56 (n  17; 95% CI, 0.33–0.90).
Table 2 shows cancer risks according to age at last hos-
pitalizationforT2Dwhenfollow-upstarted1yearlater(All
1). For some high-risk cancers, such as liver and pancre-
atic cancers, the age at hospitalization appeared not to be
critical. For stomach, ovarian, and endocrine tumors, age at
first hospitalization was associated with risk. For prostate
cancer, the lower SIR was stronger when hospitalization
took place at a young age, which was also true of the lower
risk for melanoma.
The number of hospitalizations for T2D may be an in-
dication of the severity of the disease. The effect of number
of hospitalizations was analyzed and results are presented
in Table 3. For all cancers, there were no large effects and
all the SIRs were around 1.3–1.5. Cancers at some sites, in-
cluding the upper aerodigestive tract, esophagus, liver (pri-
mary), lung, and nervous system, were associated with the
number of hospitalizations. For many other tumors, such as
colon and endometrial cancers, non-Hodgkin’s lymphoma,
and leukemia, the significant SIRs were usually observed
for patients with a lower number of hospitalizations. The
lower risk for prostate cancer was largest for patients with
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only observed in patients hospitalized once.
We also analyzed the frequencies of other diseases for
which T2D patients were hospitalized after their last hospi-
talization for T2D in order to find relationships with cancer
risk factors. However, the most common hospitalizations
were conditions related to T2D, such as coronary heart dis-
ease,stroke,atherosclerosis,cardiacfibrillation,abdominal
and chest pain, and femur fracture.
DISCUSSION
The use of hospital discharge data has great advantages,
suchasaccesstoanationwidepatientpoolandareasonably
high diagnostic accuracy, because the discharge diagnoses
areoftendeliveredbyspecialistsduringextendedexamina-
tions in the clinic. In Sweden, hospitalization for T2D may
be a secondary or tertiary referral step; T2D is diagnosed in
primary care centers that refer patients to hospital outpa-
tient clinics or directly to inpatient clinics. Hospital clinics
are directed by specialists in internal medicine or endocri-
nology/diabetology [23]. With poor diagnostic accuracy,
any effects would be expected to regress toward null. One
limitation is that not all T2D patients are hospitalized and
there is probably a selection toward severe disease presen-
tationandcomplications.However,evenamongthepresent
T2D cancer patients, 56% had been hospitalized only once
Table 1. SIRs for subsequent cancer in patients with T2D
Reference
population
a Follow-up interval (yrs)
n
Incidence/
100,000
All All 5 All 1 Familial all 1
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 21,413 6.8 228 1.71 1.49 1.95 78 1.34 1.06 1.67 176 1.50 1.28 1.73 44 1.42 1.03 1.91
Esophagus 7,613 2.4 135 2.19 1.83 2.59 42 1.51 1.09 2.04 91 1.66 1.34 2.04 19 1.33 0.80 2.09
Stomach 35,212 11.0 469 1.86 1.69 2.04 109 1.15 0.94 1.39 327 1.51 1.35 1.68 38 1.19 0.84 1.63
Small intestine 4,278 1.4 67 2.29 1.78 2.92 16 1.25 0.71 2.04 48 1.86 1.37 2.47 6 1.01 0.36 2.22
Colon 68,490 21.4 900 1.69 1.58 1.80 288 1.25 1.11 1.41 650 1.38 1.28 1.49 82 1.01 0.80 1.25
Rectum 39,077 12.3 494 1.69 1.54 1.84 171 1.35 1.16 1.57 376 1.46 1.31 1.61 78 1.61 1.28 2.01
Liver 25,304 7.9 860 4.25 3.97 4.54 247 3.12 2.74 3.53 592 3.37 3.10 3.65 102 3.56 2.90 4.33
Liver, primary 9,280 2.9 472 6.33 5.78 6.93 144 4.66 3.93 5.48 337 5.17 4.63 5.75 62 4.73 3.63 6.07
Gall bladder 8,097 2.5 165 2.62 2.24 3.05 38 1.70 1.21 2.34 110 2.04 1.68 2.46 15 2.38 1.33 3.94
Extrahepatic bile ducts 2,424 0.8 64 3.63 2.80 4.64 16 2.53 1.44 4.11 37 2.46 1.73 3.39 9 4.74 2.15 9.03
Pancreas 25,430 8.0 1,106 6.08 5.73 6.45 133 1.80 1.51 2.14 566 3.57 3.28 3.88 76 2.41 1.90 3.02
Lung 70,352 22.3 887 1.82 1.70 1.95 256 1.16 1.02 1.31 606 1.41 1.30 1.52 114 1.08 0.89 1.30
Breast 134,761 84.6 844 1.37 1.28 1.46 286 1.04 0.92 1.17 631 1.15 1.06 1.24 132 0.90 0.76 1.07
Cervix 19,248 12.1 84 2.00 1.60 2.48 26 1.59 1.04 2.33 55 1.50 1.13 1.96 9 1.20 0.54 2.29
Endometrium 30,577 19.1 374 2.22 2.00 2.45 140 1.76 1.48 2.08 281 1.85 1.64 2.08 57 1.39 1.06 1.81
Ovary 24,827 15.6 192 1.84 1.59 2.12 62 1.42 1.09 1.82 140 1.52 1.28 1.80 25 1.16 0.75 1.72
Prostate 139,169 92.9 1,458 1.10 1.04 1.16 486 0.77 0.70 0.84 985 0.84 0.78 0.89 158 0.54 0.46 0.63
Kidney 28,360 9.0 437 2.50 2.28 2.75 105 1.44 1.18 1.74 290 1.90 1.68 2.13 50 1.46 1.08 1.93
Urinary bladder 44,759 14.0 483 1.37 1.25 1.49 152 0.96 0.82 1.13 353 1.13 1.01 1.25 62 0.97 0.74 1.24
Melanoma 36,373 11.5 166 1.03 0.88 1.20 63 0.82 0.63 1.05 128 0.88 0.74 1.05 30 0.67 0.45 0.96
Skin, squamous cell 33,227 10.3 376 1.17 1.06 1.30 140 1.00 0.84 1.17 297 1.05 0.93 1.17 33 1.02 0.70 1.44
Nervous system 34,976 11.1 304 2.36 2.11 2.65 64 1.12 0.86 1.43 176 1.54 1.32 1.79 36 0.97 0.68 1.35
Thyroid gland 9,298 2.9 71 2.24 1.75 2.82 16 1.23 0.70 2.01 48 1.73 1.27 2.29 9 1.29 0.59 2.46
Endocrine glands 18,089 5.8 178 2.07 1.78 2.39 39 1.05 0.74 1.43 118 1.55 1.28 1.85 29 1.34 0.90 1.93
Non-Hodgkin’s
lymphoma
30,229 9.5 348 1.72 1.55 1.92 103 1.16 0.95 1.41 229 1.28 1.12 1.46 31 0.81 0.55 1.15
Myeloma 13,154 4.1 170 1.72 1.47 2.00 43 1.05 0.76 1.41 112 1.30 1.07 1.56 11 0.75 0.37 1.34
Leukemia 28,580 9.0 343 1.95 1.75 2.17 71 0.92 0.72 1.16 193 1.25 1.08 1.43 32 0.98 0.67 1.39
All the above 922,796 291.1 10,974 1.78 1.75 1.81 3,136 1.15 1.11 1.19 7468 1.37 1.34 1.40 1,263 1.04 0.99 1.10
aThe SIR for the reference population is 1.00.
All, follow-up started from last hospitalization; All 1, follow-up started 1 year after last hospitalization; All 5, follow-up
started 5 years after last hospitalization.
Bold type indicates that the 95% CI does not include 1.00.
Abbreviations: CI, confidence interval; O, observed number of cases; SIR, standardized incidence ratio; T2D, type 2
diabetes.
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withanelevatedriskwassimilartothatforallT2Dpatients
(22 cancers had higher risks for patients hospitalized once,
compared with 23 cancers in the All 1 period shown in
Table 1; cervical cancer was the only difference). By ex-
trapolation from regional rates, it has been estimated that
there would have been some 350,000 T2D patients in Swe-
den in the year 2004 [28]. On the other hand, at the same
time, the National Diabetes Register in Sweden only in-
cluded 57,000 patients with an age at onset 39 years
[14, 23]. The Register figure is an underestimate because
not all primary care centers or diabetes clinics participate.
Thus, the present overall figure of 125,126 patients hospi-
talized at age 39 years and defined as having T2D by the
ICD-10 appears to lie between the National Diabetes Reg-
ister number, corrected for full coverage, and the extrapo-
lated figure for T2D patients. Even if some type 1 diabetes
patients could not be excluded, they would not essentially
contribute to the present results because of the unclear as-
sociation with any risk for cancer [18]. Regarding the
present patients series, we discussed diagnostic accuracy
and coverage in more detail in a recent article [13]. We had
nodataonmanyriskfactorsofortreatmentforT2D,which
might have influenced the results. The data were adjusted
for the risk factors for which data were available, including
obesity, based on hospital records on patients ever dis-
charged with this condition. This adjustment, however, had
hardly any effect on the risks, in agreement with a U.S.
study [19].
Another issue relating to the interpretation of the results
is the change in SIR depending on the definition of the fol-
low-up time (All, All 1, and All 5). For all cancers, the
Table 2. SIRs for subsequent cancers in patients with T2D by age at hospitalization when follow-up was started 1 year after
last hospitalization
Cancer
Age at hospitalization, yrs (n of patients)
<50 (n  9,478) 50–59 (n  16,435) 60–74 (n  47,745) >74 (n  51,468)
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 19 1.55 0.93 2.42 41 1.64 1.18 2.23 85 1.70 1.36 2.10 31 1.02 0.69 1.45
Esophagus 6 1.30 0.47 2.84 23 2.11 1.33 3.17 43 1.81 1.31 2.44 19 1.24 0.74 1.93
Stomach 23 2.34 1.48 3.51 29 1.06 0.71 1.52 146 1.54 1.30 1.81 129 1.52 1.27 1.81
Small intestine 4 1.78 0.46 4.60 9 1.94 0.88 3.69 24 2.16 1.38 3.21 11 1.42 0.70 2.55
Colon 23 0.96 0.61 1.45 78 1.17 0.93 1.46 342 1.65 1.48 1.83 207 1.20 1.04 1.38
Rectum 23 1.44 0.91 2.16 59 1.44 1.09 1.86 201 1.73 1.50 1.99 93 1.10 0.89 1.35
Liver 31 3.59 2.44 5.10 87 3.75 3.01 4.63 315 4.08 3.64 4.56 159 2.38 2.03 2.78
Liver, primary 17 4.15 2.41 6.65 54 5.39 4.05 7.04 185 6.39 5.50 7.38 81 3.66 2.91 4.55
Gall bladder 7 4.64 1.84 9.61 9 1.60 0.72 3.05 59 2.48 1.89 3.20 35 1.52 1.06 2.12
Extrahepatic bile ducts 3 5.26 0.99 15.58 8 4.44 1.90 8.80 13 1.96 1.04 3.36 13 2.14 1.13 3.67
Pancreas 35 3.49 2.43 4.86 77 3.05 2.40 3.81 280 3.91 3.46 4.39 174 3.37 2.89 3.92
Lung 49 1.34 0.99 1.78 140 1.54 1.30 1.82 325 1.52 1.36 1.70 92 1.01 0.82 1.24
Breast 55 0.85 0.64 1.11 94 0.90 0.73 1.10 272 1.26 1.11 1.42 210 1.28 1.11 1.46
Cervix 4 1.04 0.27 2.70 11 1.78 0.88 3.20 20 1.21 0.74 1.88 20 1.97 1.20 3.05
Endometrium 18 1.28 0.76 2.03 46 1.45 1.06 1.94 148 2.20 1.86 2.59 69 1.78 1.39 2.26
Ovary 21 2.20 1.36 3.37 16 0.90 0.51 1.46 76 1.83 1.44 2.29 27 1.17 0.77 1.70
Prostate 37 0.49 0.35 0.68 143 0.67 0.56 0.78 527 0.95 0.87 1.04 278 0.83 0.74 0.93
Kidney 17 1.25 0.73 2.01 58 1.99 1.51 2.58 156 2.18 1.85 2.55 59 1.53 1.16 1.97
Urinary bladder 20 0.95 0.58 1.47 62 1.17 0.90 1.51 179 1.26 1.08 1.45 92 0.95 0.77 1.17
Melanoma 14 0.69 0.38 1.16 17 0.52 0.31 0.84 62 1.06 0.81 1.36 35 1.04 0.72 1.44
Skin, squamous cell 11 1.09 0.54 1.96 29 1.13 0.76 1.62 113 1.08 0.89 1.30 144 1.00 0.85 1.18
Nervous system 14 0.84 0.46 1.42 35 1.23 0.85 1.71 91 1.84 1.48 2.26 36 1.85 1.30 2.57
Thyroid gland 5 1.48 0.47 3.49 6 1.18 0.42 2.58 27 2.34 1.54 3.41 10 1.27 0.61 2.35
Endocrine glands 18 1.95 1.15 3.09 29 1.74 1.17 2.51 48 1.37 1.01 1.81 23 1.50 0.95 2.26
Non-Hodgkin’s lymphoma 14 0.99 0.54 1.67 35 1.17 0.81 1.63 105 1.34 1.10 1.63 75 1.33 1.04 1.66
Myeloma 3 0.60 0.11 1.78 21 1.67 1.03 2.56 53 1.34 1.00 1.75 35 1.20 0.84 1.67
Leukemia 7 0.61 0.24 1.27 38 1.49 1.05 2.05 78 1.13 0.89 1.41 70 1.43 1.11 1.80
All the above 471 1.13 1.03 1.24 1,183 1.25 1.18 1.32 3,716 1.53 1.49 1.59 2,098 1.26 1.21 1.32
Bold type indicates that the 95% CI does not include 1.00.
Abbreviations: CI, confidence interval; O, observed number of cases; SIR, standardized incidence ratio; T2D, type 2
diabetes.
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tion for T2D, which is likely to be a result of lead time bias.
The Cancer Registry records all new cases of cancer, and
close to 100% of the cases are histologically or cytologi-
cally confirmed [24]. Thus, lead time bias only shifts the
diagnoses earlier, and because diagnostic accuracy is not
compromised, even early cases are true cancers. Thus,
while the All follow-up period overestimates, the All 1
andAll5periodsarelikelytounderestimatethetruerisk.
The avoidance of lead time bias was also the reason for our
selectionofstartingfollow-upfromthelasthospitalization.
It is likely that cancers would be diagnosed earlier in per-
sonswhoarehospitalized,evenforconditionsnotrelatedto
cancer, than in nonhospitalized persons. However, the ef-
fects are expected to be small [29–33].
The literature on T2D and cancer is far too extensive to
be covered here, and we refer to the five reviews published
since 2007 [16–18, 21–22]. One of them concluded that an
association with pancreatic cancer has been established,
and that an association with colorectal, liver, endometrial,
and bladder cancers is supported by some data, similar to
the inverse association with prostate cancer [18]. In the
present study, we confirmed all these conditional associa-
tions in reporting increased risks for 25 cancers in the All
period and increased risks for 23 cancers in the All 1 pe-
riod. The risks were highest for liver cancer through all fol-
low-uptimes,exceptfortheAllperiod,inwhichtheriskfor
pancreatic cancer was highest. Five years after the last hos-
pitalizationforT2D(theAll5period),11cancershadex-
cessrisks,withlivercancershowingthehighestriskof3.12
(primary liver cancer, 4.66), followed by pancreatic (1.80),
endometrial (1.76), cervical (1.59), and esophageal (1.51)
Table 3. SIRs for subsequent cancers in patients with T2D by number of hospitalizations when follow-up was started 1 year
after last hospitalization
Cancer
n of hospitalizations for T2D (n of patients)
1( n  70,108) 2 (n  22,532) 3–5 (n  21,324) >5( n  11,162)
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 119 1.46 1.21 1.74 22 1.18 0.74 1.79 25 1.91 1.23 2.82 10 2.36 1.13 4.36
Esophagus 53 1.41 1.05 1.84 23 2.60 1.65 3.91 8 1.29 0.55 2.56 7 3.48 1.38 7.22
Stomach 222 1.53 1.33 1.74 54 1.49 1.12 1.94 36 1.37 0.96 1.89 15 1.67 0.93 2.76
Small intestine 31 1.75 1.19 2.48 5 1.21 0.38 2.85 9 3.01 1.36 5.74 3 3.23 0.61 9.55
Colon 455 1.42 1.29 1.56 107 1.37 1.12 1.65 73 1.32 1.04 1.66 15 0.87 0.49 1.44
Rectum 248 1.41 1.24 1.59 69 1.62 1.26 2.05 43 1.45 1.05 1.96 16 1.73 0.98 2.81
Liver 351 3.00 2.69 3.33 126 4.18 3.48 4.97 86 3.97 3.18 4.91 29 4.18 2.80 6.02
Liver, primary 190 4.32 3.72 4.97 74 6.73 5.29 8.46 56 7.26 5.49 9.44 17 6.97 4.05 11.18
Gall bladder 67 1.91 1.48 2.42 25 2.63 1.70 3.89 15 2.12 1.18 3.51 3 1.34 0.25 3.96
Extrahepatic bile ducts 25 2.50 1.62 3.70 6 2.33 0.84 5.10 2 1.05 0.10 3.85 4 6.78 1.76 17.53
Pancreas 383 3.60 3.24 3.97 94 3.52 2.85 4.31 70 3.63 2.83 4.59 19 3.13 1.88 4.90
Lung 376 1.26 1.13 1.39 108 1.55 1.27 1.88 86 1.81 1.45 2.24 36 2.42 1.69 3.35
Breast 418 1.14 1.03 1.25 107 1.12 0.92 1.35 75 1.15 0.90 1.44 31 1.50 1.02 2.14
Cervix 31 1.27 0.86 1.80 11 1.72 0.85 3.09 13 2.94 1.56 5.04 0
Endometrium 196 1.92 1.66 2.21 48 1.86 1.37 2.47 29 1.62 1.08 2.33 8 1.37 0.59 2.72
Ovary 88 1.44 1.15 1.77 21 1.33 0.82 2.03 25 2.23 1.44 3.30 6 1.67 0.60 3.66
Prostate 717 0.86 0.80 0.93 153 0.83 0.71 0.98 87 0.70 0.56 0.87 28 0.71 0.47 1.03
Kidney 185 1.78 1.53 2.05 56 2.19 1.65 2.85 40 2.27 1.62 3.10 9 1.59 0.72 3.04
Urinary bladder 248 1.14 1.00 1.29 53 1.06 0.79 1.39 34 0.98 0.68 1.37 18 1.64 0.97 2.60
Melanoma 76 0.75 0.59 0.94 25 1.09 0.70 1.61 22 1.40 0.88 2.13 5 1.02 0.32 2.41
Skin, squamous cell 209 1.07 0.93 1.22 47 1.01 0.74 1.35 28 0.88 0.58 1.27 13 1.31 0.69 2.24
Nervous system 101 1.29 1.05 1.56 42 2.23 1.61 3.02 19 1.49 0.89 2.33 14 3.52 1.92 5.92
Thyroid gland 33 1.74 1.20 2.45 6 1.28 0.46 2.82 6 1.88 0.68 4.12 3 2.97 0.56 8.79
Endocrine glands 77 1.49 1.17 1.86 23 1.80 1.14 2.70 14 1.56 0.85 2.63 4 1.43 0.37 3.71
Non-Hodgkin’s lymphoma 157 1.28 1.09 1.50 39 1.32 0.94 1.81 29 1.42 0.95 2.04 4 0.63 0.16 1.62
Myeloma 78 1.33 1.05 1.66 17 1.19 0.69 1.92 15 1.49 0.83 2.47 2 0.61 0.06 2.25
Leukemia 135 1.27 1.06 1.50 38 1.49 1.05 2.05 16 0.91 0.52 1.48 4 0.74 0.19 1.91
All the above 4,987 1.33 1.30 1.37 1,294 1.45 1.37 1.53 888 1.44 1.35 1.54 299 1.53 1.36 1.71
Bold type indicates that the 95% CI does not include 1.00.
Abbreviations: CI, confidence interval; O, observed number of cases; SIR, standardized incidence ratio; T2D, type 2
diabetes.
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tract, and esophageal cancers may suggest impairment of
defenses against viral transformation. Esophageal and up-
per aerodigestive tract cancers are related to smoking, but
because the SIR for lung cancer was only 1.16 (for the All
5 period), smoking alone cannot explain the elevated
risks [7]. However, excessive consumption of alcohol in
combination with smoking may contribute to a greater risk
for these cancers [8]. T2D has been assumed to interfere
with estrogen metabolism, and previous studies have
shown evidence for higher risks for endometrial and post-
menopausal breast cancers [16, 18]. Most breast cancer pa-
tients in the present population, aged 39 years at the start
of the follow-up period, would be postmenopausal and the
higher breast cancer risk was only seen for follow-up peri-
ods that started shortly after hospitalization for T2D. In
contrast, the higher risks for endometrial and ovarian can-
cers were clear. Obesity is another shared risk factor be-
tween T2D and cancers of the endometrium, kidney, colon,
and (postmenopausal) breast; however, the applied adjust-
ment for obesity did not change the present results [18, 34].
We lacked data on the treatment for T2D and cannot distin-
guish between the effects caused by the disease and those
caused by the treatment received [21]. However, one can
assumethattreatment-relatedeffectswererelatedtotheage
at hospitalization and the number of hospitalizations, pa-
rameters that did not correlate with risk for most cancers.
To our knowledge, no previous study has followed can-
cer in familial T2D patients. There were a few differences
between familial T2D patients and all T2D patients. Nota-
bly, the risk for prostate cancer was lower in familial pa-
tients and it reached an SIR of 0.42 in patients with three to
five hospitalizations and 0.10 in patients with more than
five hospitalizations. The risks for pancreatic cancer and
melanoma were also lower in familial patients than in all
patients. The lower risk for prostate cancer has been ob-
served in other studies, which is consistent with a lower
level of serum prostate-specific antigen in diabetics [35].
The effects have been ascribed to low androgen levels, but
therelationshipsremaintobeestablished[17, 36].Thedata
on cancer risk for familial T2D patients suggest that the ge-
neticandenvironmentalmechanismscontributingtofamil-
ial T2D appear not to be risk factors for cancer. These data
indicatethatobesityisnotlikelytobealargeconfounderof
the present associations because high heritability of obesity
should lead to higher risks for cancer in familial T2D pa-
tients [37]. Similarly, smoking clusters in families [38];
thus,thelackofexcessfamilialriskatsmoking-relatedsites
(esophagus, kidney) suggests that smoking was not a con-
founder. The markedly lower risk for prostate cancer ap-
peared not to be a chance finding. Unraveling of the
underlyingmechanismsmaygiveimportantcluesaboutthe
shared pathways of T2D and prostate cancer.
In summary, this large study on Swedish T2D patients
found an elevated risk for 23 cancers when follow-up
started 1 year after hospitalization for T2D. The large num-
ber of novel cancer sites may be explained by the high sta-
tistical power of the study and, probably, by patient
selection toward those with severe disease leading to hos-
pitalization. The highest risks were found for liver and pan-
creaticcancers.Theincreasedrisksattheseandmanyother
sites cannot be explained by the risk factors for familial
T2D because no excess risks were observed in familial di-
abetics. Rather, the effects on many cancers may be related
to the multitude of metabolic disturbances of T2D. The de-
creased risks for prostate cancer and melanoma remain in-
triguing and challenging for the future.
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